These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 36658088)
1. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma. Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088 [TBL] [Abstract][Full Text] [Related]
2. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma. Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736 [TBL] [Abstract][Full Text] [Related]
3. Targeting the mTOR pathway using novel ATP‑competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma. Amin AG; Jeong SW; Gillick JL; Sursal T; Murali R; Gandhi CD; Jhanwar-Uniyal M Int J Oncol; 2021 Oct; 59(4):. PubMed ID: 34523696 [TBL] [Abstract][Full Text] [Related]
4. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261 [TBL] [Abstract][Full Text] [Related]
5. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
6. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma. Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046 [TBL] [Abstract][Full Text] [Related]
7. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects. Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457 [TBL] [Abstract][Full Text] [Related]
8. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets. Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD Cells; 2024 Feb; 13(5):. PubMed ID: 38474373 [TBL] [Abstract][Full Text] [Related]
9. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909 [TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer. Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849 [TBL] [Abstract][Full Text] [Related]
11. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692 [TBL] [Abstract][Full Text] [Related]
12. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes. Weinberg MA Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392 [TBL] [Abstract][Full Text] [Related]
13. Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment. Heinzen D; Divé I; Lorenz NI; Luger AL; Steinbach JP; Ronellenfitsch MW Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510109 [TBL] [Abstract][Full Text] [Related]
14. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957 [TBL] [Abstract][Full Text] [Related]
15. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612 [TBL] [Abstract][Full Text] [Related]
16. Head and neck cancer stem cell maintenance relies on mTOR signaling, specifically involving the mechanistic target of rapamycin complexes 1 and 2 (mTORC1 and mTORC2). Almeida LO; Silva LC; Emerick C; Amorim Dos Santos J; Castilho RM; Squarize CH Arch Oral Biol; 2024 Jan; 157():105840. PubMed ID: 37939517 [TBL] [Abstract][Full Text] [Related]
17. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors. Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505 [TBL] [Abstract][Full Text] [Related]
18. Role of mTOR in glioblastoma. Duzgun Z; Eroglu Z; Biray Avci C Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. Fan QW; Weiss WA Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077 [TBL] [Abstract][Full Text] [Related]
20. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells. Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]